<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220313054273N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-09-27</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>The effect of contrast agent reduction on the image quality of pulmonary Computed Tomography</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of contrast agent reduction on the image quality of pulmonary Computed Tomography using a standard reconstruction available in the conventional CT system</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/64650</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Diagnostic, Randomization description: To allocate patients in intervention and control groups, simple random allocation method will be used. We asked the SPSS software to provide us 20 values randomly between 1 to 40. The software gave us the values 5, 3, 13, 18, 2, 14, 10, 1, 35, 37, 23, 32, 8, 16, 33, 36, 39, 9, 22, 28. By drawing lots between the control and intervention groups, we assigned these numbers to the intervention group. Then, the rest of the numbers, between 1 and 40, were assigned to the control group. 
In this way, we will assign the patients as control and intervention groups right from the beginning of the study, among the patients who were referred to the CT scan department of Namazi hospital, with the suspension of pulmonary embolism and having the inclusion criteria for entering the study. 
From the above random numbers, the first, second, and third patients are to be included in the intervention group. The intervention group will be scanned by reducing contrast agent protocol (pulmonary CT Angio). The fourth, fifth, and sixth patients referred will be allocated to the control group and they will be scanned by the standard dose of the contrast agent protocol (pulmonary CT Angio).
Other referred patients who are candidates for the study will be placed in the intervention or control groups based on the serial number of their referrals and the matching numbers in the above-mentioned allocations, Blinding description: In this study, the investigator (radiologists who evaluate the quality of pulmonary CTA) and patients will not be aware of the scanning protocol (they are blind to the amount of contrast agent). Only, technologists responsible for scanning patients and the students responsible for performing the study are aware of the amount of contrast agent.</study_design>
      <phase>3</phase>
      <hc_freetext>pulmonary thromboembolism.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients suspected of pulmonary embolism referred to Namazi Hospital (Shiraz) will be scanned by contrast agent reduction protocol. The amount of injected contrast agent to the patients in the intervention group will be 0.7 ml/kg of body weight. The Pecnograph contains 300mgI/ml (milligram iodine per millilitre) made in Iran and is the most widely available contrast agent. This contrast agent will be used to scan patients in the intervention group. These patients will be scanned by a 16-Slice LightSpeed GE Healthcare CT system, made in the USA, at 100kVp. The pulmonary CT Angio images of patients in the intervention group will be reconstructed by Filter Back Projection (FBP), made in the USA. FBP is a standard image reconstruction algorithm and is available in conventional CT systems. Conventional CT systems are used to scan patients in most hospitals affiliated with the Shiraz University of Medical Sciences. Intervention 2: Control group: Patients suspected of pulmonary embolism referred to Namazi Hospital (Shiraz) will be scanned by standard protocol (pulmonary CT Angio). The amount of injected contrast agent to the patients in the control group will be 1.0 milliliter per kilogram of the patient’s body weight. The Pecnograph contains 300mgI/ml (milligram iodine per milliliter) made in Iran is the most widely available contrast agent. This contrast agent will be used to scan patients in the control group. The patients in the control group will be scanned by a 16-Slice LightSpeed GE Healthcare CT system, made in the USA, at 120kVp. The pulmonary CT Angio images of patients in the control group will be reconstructed by Filter Back Projection (FBP), made in the USA. FBP is a standard image reconstruction algorithm and is available in conventional CT systems. Conventional CT systems are used to scan patients in most hospitals affiliated with the Shiraz University of Medical Sciences.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Part of the data can be shared after unidentified

When:
6 months after publication

To whom:
Interested researchers in this field

Conditions:
Using for research works

Where to obtain:
Research and technology deputy

How to obtain:
Sending an Email to research and technology deputy.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Rezvan Ravanfar Haghighi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Medical Imaging Research Centre, 8th Floor, Mohammad Rasolallah Research Tower, Khalili street</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7193635899</zip>
        <telephone>+98 71 3628 1464</telephone>
        <email>sravanfarr@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Rezvan Ravanfar Haghighi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Medical Imaging Research Centre, 8th Floor, Mohammad Rasolallah Research Tower, Khalili street</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7193635899</zip>
        <telephone>+98 71 3628 1464</telephone>
        <email>sravanfarr@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Suspicion pulmonary emboly as seen from clinical indication
Abnormal levels of plasma D-dimer
Lower extremity deep vein thrombosis</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Severe pneumonia and atelectasis
Confirmed pregnancy or suspected but unconfirmed pregnancy
Critically ill patient or patients hospitalized in ICU
Allergy to iodine contrast agents
Creatinine&gt;1.36 mg/dL
Age &lt; 18 years
GFR less than 60ml/min/1.73m2
Body-Mass Index (BMI) greater than 30 kg/m2</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>I26</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Pulmonary embolism</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Diagnosis</i_code>
      <i_code>Diagnosis</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients suspected of pulmonary embolism referred to Namazi Hospital (Shiraz) will be scanned by contrast agent reduction protocol. The amount of injected contrast agent to the patients in the intervention group will be 0.7 ml/kg of body weight. The Pecnograph contains 300mgI/ml (milligram iodine per millilitre) made in Iran and is the most widely available contrast agent. This contrast agent will be used to scan patients in the intervention group. These patients will be scanned by a 16-Slice LightSpeed GE Healthcare CT system, made in the USA, at 100kVp. The pulmonary CT Angio images of patients in the intervention group will be reconstructed by Filter Back Projection (FBP), made in the USA. FBP is a standard image reconstruction algorithm and is available in conventional CT systems. Conventional CT systems are used to scan patients in most hospitals affiliated with the Shiraz University of Medical Sciences.</i_keyword>
      <i_keyword>Control group: Patients suspected of pulmonary embolism referred to Namazi Hospital (Shiraz) will be scanned by standard protocol (pulmonary CT Angio). The amount of injected contrast agent to the patients in the control group will be 1.0 milliliter per kilogram of the patient’s body weight. The Pecnograph contains 300mgI/ml (milligram iodine per milliliter) made in Iran is the most widely available contrast agent. This contrast agent will be used to scan patients in the control group. The patients in the control group will be scanned by a 16-Slice LightSpeed GE Healthcare CT system, made in the USA, at 120kVp. The pulmonary CT Angio images of patients in the control group will be reconstructed by Filter Back Projection (FBP), made in the USA. FBP is a standard image reconstruction algorithm and is available in conventional CT systems. Conventional CT systems are used to scan patients in most hospitals affiliated with the Shiraz University of Medical Sciences.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The objective image quality of pulmonary CT Angio will be determined by radiologists through a scoring system. The quantitative image quality will be determined by quantitative parameters such as Signal-to-Noise Ratio. Timepoint: The CT images will be sent to Picture Archiving and Communication System immediately after the scanning procedure completed. Then the qualitative and quantitative evaluation of the image quality of pulmonary CT Angio will be performed. Method of measurement: Quantitative pulmonary Computed Tomography angiography (CTA) image quality will be measured by the Signal-to-Noise Ratio (SNR). The mean CT density or CT- number of the main pulmonary arteries (left and right) will be measured. The CT-numbers will be measured by selecting the Region of Interest (ROI) inside the left and right main pulmonary arteries, filled with the contrast agent. This CT number is known as signal. The muscles surrounding the scapula is known as background, being a region without contrast agent. An ROI will be selected in the background. Then, the standard deviation of the CT-number will be measured for the background. These measured parameters will be used to calculate SNR. Qualitative pulmonary CT Angio (CTA) image quality will be measured by visual assessment. In this method, two expert radiologists will report the image quality using a scoring system. In this system measuring the image quality is measured in a scale of 5 in which the scores assigned as follows, (1) undiagnosable (2) limited diagnostic value (3) sufficient diagnostic value (4) good image quality (5) excellent diagnostic value. If the mean score equal to or greater than 3, it will be reported as an acceptable diagnostic value.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-07-08</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Medical Imaging Research Centre, 8th Floor, Mohammad Rasolallah Research Tower, Khalili street Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
